In this video, Xavier Leleu, MD, PhD, Poitiers University Hospital, Poitiers, France, discusses a session held at COMy 2023 which focused on precursor states in myeloma, including the identification of monoclonal gammopathy of undetermined significance (MGUS) and how to minimize the risk of disease progression. Prof. Leleu emphasizes the importance of identifying this patient group and speculates on both potential benefits and consequences of treating patients at the MGUS level. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.